Live price temporarily unavailable.
Context Therapeutics (CNTX) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$2.57M | −$10.5M | −$15.4M | −$25.1M | −$29.9M | −$39.7M |
| Net income | $6.64M | −$10.5M | −$14.8M | −$24.0M | −$26.7M | −$36.1M |
| EPS (diluted) | −$3.96 | −$3.69 | −$0.93 | −$1.50 | −$0.46 | −$0.38 |
| Balance sheet | ||||||
| Cash and equivalents | $290.7K | $49.6M | $35.5M | $14.4M | $94.4M | $66.0M |
| Total assets | $467.3K | $51.3M | $38.0M | $16.1M | $98.1M | $68.5M |
| Total liabilities | $9.62M | $3.03M | $3.21M | $4.19M | $2.86M | $8.02M |
| Shareholders' equity | −$16.9M | $48.3M | $34.8M | $11.9M | $95.3M | $60.5M |
| Cash flow | ||||||
| Operating cash flow | −$1.03M | −$8.80M | −$13.5M | −$21.0M | −$14.6M | −$26.4M |
| Capital expenditure | — | $0 | $36.8K | $0 | $7.32K | $33.9K |
| Free cash flow | — | −$8.80M | −$13.6M | −$21.0M | −$14.6M | −$26.4M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$18.7M | −$4.31M | −$5.53M | −$9.76M | −$10.6M | −$13.8M | −$9.34M | −$15.0M |
| Net income | −$17.5M | −$3.34M | −$4.58M | −$8.83M | −$9.69M | −$13.0M | −$8.68M | −$14.6M |
| EPS (diluted) | −$0.22 | $0.03 | −$0.05 | −$0.09 | −$0.10 | −$0.14 | −$0.09 | −$0.15 |
| Balance sheet | ||||||||
| Cash and equivalents | $84.8M | $94.4M | $89.4M | $83.5M | $76.9M | $66.0M | $54.5M | $43.0M |
| Total assets | $86.3M | $98.1M | $93.0M | $87.2M | $79.2M | $68.5M | $58.9M | $46.1M |
| Total liabilities | $2.47M | $2.86M | $1.98M | $4.61M | $6.06M | $8.02M | $6.66M | $7.96M |
| Shareholders' equity | $83.9M | $95.3M | $91.0M | $82.5M | $73.2M | $60.5M | $52.2M | $38.2M |
| Cash flow | ||||||||
| Operating cash flow | −$1.93M | −$4.91M | −$5.03M | −$5.84M | −$6.58M | −$8.94M | −$11.4M | −$7.02M |
| Capital expenditure | $7.32K | $0 | $33.9K | $0 | $0 | $0 | $37.3K | $18.5K |
| Free cash flow | −$1.94M | −$4.91M | −$5.06M | −$5.84M | −$6.58M | −$8.94M | −$11.5M | −$7.04M |
From Context Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Context Therapeutics in our feed yet.